M
Myrto Moutafi
Researcher at Yale University
Publications - 25
Citations - 159
Myrto Moutafi is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 7 publications receiving 8 citations.
Papers
More filters
Journal ArticleDOI
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
Myrto Moutafi,Charles J. Robbins,Vesal Yaghoobi,Aileen I. Fernandez,Sandra Martinez-Morilla,Vasiliki Xirou,Yalai Bai,Yang Song,Patricia Gaule,Joseph S. Krueger,Kenneth Bloom,Salisha Hill,Daniel C. Liebler,Regan Fulton,David L. Rimm +14 more
TL;DR: In this article , the authors used the AQUA method of quantitative immunofluorescence to test a range of antibody concentrations to maximize the sensitivity within the lower range of HER2 expression.
Journal ArticleDOI
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
Myrto Moutafi,Charles J. Robbins,Vesal Yaghoobi,Aileen I. Fernandez,Sandra Martinez-Morilla,Vasiliki Xirou,Yalai Bai,Yang Song,Patricia Gaule,Joseph S. Krueger,Kenneth Bloom,Salisha Hill,Daniel C. Liebler,Regan Fulton,David L. Rimm +14 more
TL;DR: In this article , the authors used the AQUA method of quantitative immunofluorescence to test a range of antibody concentrations to maximize the sensitivity within the lower range of HER2 expression.
Journal ArticleDOI
A new tool for technical standardization of the Ki67 immunohistochemical assay.
Thazin Nwe Aung,Balazs Acs,Jonathan Warrell,Yalai Bai,Patricia Gaule,Sandra Martinez-Morilla,Ioannis A. Vathiotis,Saba Shafi,Myrto Moutafi,Mark Gerstein,Benjamin Freiberg,Regan Fulton,David L. Rimm +12 more
TL;DR: In this article, a cell line microarray system was developed for the standardization of the Karpas 299 or Jurkat cells (Ki67+) with Sf9 (Spodoptera frugiperda) (ki67-) cells in incremental standardized ratios.
Journal ArticleDOI
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
TL;DR: In this paper, the authors summarized the data supporting the integration of PARP inhibitors into HNSCC therapeutic strategy and provided a rational research strategy for the design of trials combining PARPi and PD-1 checkpoint inhibitors.
Journal ArticleDOI
Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
TL;DR: Despite some early promising signs, a lot of work is required in the field of clinical studies, and larger patient cohorts are needed in order for more valid conclusions to be extracted, regarding the potential of HDACi as mainstream treatment options for melanoma.